Complementing Your Psychotherapy

Video

VistaGen Therapeutics CEO Shawn Singh discusses what he and VistaGen are doing to create and improve treatments that complement your practice.

Shawn K. Singh, JD, is the CEO of VistaGen Therapeutics, Inc.

To see more of what VistaGen is doing to improve the medicinal treatments for anxiety and depression, see Benzodiazepines Hit With Boxed Warning by FDA.

Related Videos
Experts on MDD.
Experts on MDD.
“What we’re striving to do is conquer the unmet needs that are still here with treating ADHD, especially from a medication standpoint.”
Work takes up one-third of a patient’s life—it is important that we pay attention to it.
A new treatment in development is poised to be a game-changer for patients with postpartum depression.
Related Content

Topline Phase 2 Data Support Efficacy, Tolerability, and Favorable Safety of Treatment for PTSD

September 26th 2023

Blue Light Blockers: A Behavior Therapy for Mania

October 7th 2021

Non-Psychiatric Medications With Potential to Worsen Symptoms in Major Depression

September 25th 2023

Treating ‘Morally Objectionable’ Patients

September 27th 2021

Psychedelics Research Roundup: September 22

September 22nd 2023

Phase 3 Study Supports Efficacy, Safety of New Chemical Entity for MDD

September 20th 2023

Topline Phase 2 Data Support Efficacy, Tolerability, and Favorable Safety of Treatment for PTSD

September 26th 2023

Blue Light Blockers: A Behavior Therapy for Mania

October 7th 2021

Non-Psychiatric Medications With Potential to Worsen Symptoms in Major Depression

September 25th 2023

Treating ‘Morally Objectionable’ Patients

September 27th 2021

Psychedelics Research Roundup: September 22

September 22nd 2023

Phase 3 Study Supports Efficacy, Safety of New Chemical Entity for MDD

September 20th 2023

Topline Phase 2 Data Support Efficacy, Tolerability, and Favorable Safety of Treatment for PTSD

September 26th 2023

Blue Light Blockers: A Behavior Therapy for Mania

October 7th 2021

Non-Psychiatric Medications With Potential to Worsen Symptoms in Major Depression

September 25th 2023

Treating ‘Morally Objectionable’ Patients

September 27th 2021

Psychedelics Research Roundup: September 22

September 22nd 2023

Phase 3 Study Supports Efficacy, Safety of New Chemical Entity for MDD

September 20th 2023
© 2023 MJH Life Sciences

All rights reserved.